Table 5.
Pooled any‐grade adverse effects rate (any‐grade AEs%) and modified any‐grade adverse effects rate (any‐grade AEs%) in non‐small‐cell lung cancer (NSCLC) patients for included studies
| Study | Any‐grade AEs% (predeleted) | Study | Any‐grade AEs% (postdeleted) | ||||
|---|---|---|---|---|---|---|---|
| Median | 95% CI | Median | 95% CI | ||||
| Total | 60% | 46–75% | Total | 61% | 50–73% | ||
| 2014 | Antonia et al. | 85% | 74–95% | 2014 | Antonia et al. | 85% | 74–95% |
| 2014 | Ramalingam et al. | 71% | 63–79% | 2014 | Ramalingam et al. | 71% | 63–79% |
| 2014 | Rizvi et al. | 73% | 58–88% | 2014 | Rizvi et al. | 73% | 58–88% |
| 2015 | Bauer et al. | 13% | 9–18% | 2015 | Borghaei et al. | 68% | 63–74% |
| 2015 | Borghaei et al. | 68% | 63–74% | 2015 | Brahmer et al. | 58% | 50–66% |
| 2015 | Brahmer et al. | 58% | 50–66% | 2015 | Gettinger et al. | 41% | 33–50% |
| 2015 | Gettinger et al. | 41% | 33–50% | 2015 | Rizvi et al. | 74% | 66–82% |
| 2015 | Rizvi et al. | 74% | 66–82% | 2016 | Brustugun et al. | 31% | 19–43% |
| 2016 | Brustugun et al. | 31% | 19–43% | 2016 | Crino et al. | 29% | 24–33% |
| 2016 | Crino et al. | 29% | 24–33% | 2016 | Gettinger et al. | 71% | 59–84% |
| 2016 | Gettinger et al. | 71% | 59–84% | 2017 | Hellmann et al. | 43% | 32–54% |
| 2016 | Rizvi et al. | 95% | 89–100% | 2016 | Nishio et al. | 84% | 76–92% |
| 2017 | Hellmann et al. | 43% | 32–54% | 2017 | Carbone et al. | 71% | 66–75% |
| 2016 | Nishio et al. | 84% | 76–92% | Overall (I 2 = 96.4%, P < 0.001); Egger's test (P = 0.367) | |||
| 2017 | Carbone et al. | 71% | 66–75% | ||||
| Overall (I 2 = 98.4%, P < 0.001); Egger's test (P = 0.175) | |||||||